The MAP4K4-specific inhibitor GNE-495 exerts multiple therapeutic effects against pancreatic cancer, including inhibiting cell proliferation, inducing apoptosis, and reducing tumour stroma. Here, MAP4K4 is linked to pancreatic neoplasm.